Loews Corporation reported a net income of $306 million for Q3 2026, down from $504 million in the same period last year, mainly due to a $125 million after-tax charge from CNA Financial's long-term care reserve updates and increased catastrophe losses. Boardwalk Pipelines saw lower net income due to higher operating expenses and impairment charges, while Loews Hotels improved earnings thanks to higher room rates and occupancy. Despite the income drop, Loews repurchased 1.6 million shares and maintained a strong cash position of $4.4 billion. Investors should watch how CNA's reserve adjustments and investment income evolve in coming quarters.
Loews Corporation's Q3 2026 net income was $306 million, down from $504 million last year. For readers following the Financials sector, here is Pluang's market snapshot as of Nov 02, 2026 17:11 WIB: of 142 priced Financials-sector US stocks, 80 rose and 22 fell. Notable movers include CLSK at USD 7.83 (+2.29%), MFG at USD 9.88 (+2.28%), and BMNR at USD 20.63 (+2.23%).
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
